Effectiveness of Dapagliflozin for Weight Loss

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT03968224

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
Centro Medico Nacional Siglo XXI IMSS (from the registry)
Registry
  • NCT NCT03968224
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03968224. Randomized; no masking; primary purpose treatment. Start 2018-08-04 (actual); primary completion 2024-07-31 (actual). Results posted on 2025-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effectiveness of Dapagliflozin for Weight Loss
Condition
PreDiabetes
Condition
Obesity, Morbid
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dapagliflozin/Metformin
Intervention (Drug)
Metformin
Lead sponsor
Centro Medico Nacional Siglo XXI IMSS (class: other)

Record details

Record id
cardio:ct-nct03968224
Content hash
b26c9255fe335ea01fdfa9eb802c28bb571be91a271d39f0062c4b7c8302742a